Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: Synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease

Metallomics

Volumn 9, Issue 7, 2017, Pages 852-864

  Gotsbacher, Michael P ^a   Telfer, Thomas J ^a   Witting, Paul K ^a   Double, Kay L ^a   Finkelstein, David I ^b   Codd, Rachel ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; BENZOIC ACID; BIOCHEMISTRY; BLOOD; CHELATION; CHEMICALS REMOVAL (WATER TREATMENT); MAMMALS; NEURODEGENERATIVE DISEASES; NEURONS; PROPIONIC ACID;

ANTI-OXIDANT ACTIVITIES; ANTIOXIDANT PROPERTIES; CARBOXYLIC ACID DERIVATIVES; DOPAMINERGIC NEURONS; NEURODEGENERATIVE DISORDERS; PLASMA PROTEIN BINDING; REACTIVE OXYGEN SPECIES; THERAPEUTIC STRATEGY;

IRON COMPOUNDS;

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; DESFERRIOXAMINE B DERIVATIVE; IRON CHELATING AGENT; N1 HYDROXY N1 [5 [4 [HYDROXY[1 (6 HYDROXY 2,5,7,8 TETRA METHYLCHROMANE 2 CARBOXAMIDO) 1LAMBDA5,5LAMBDA3 PENTYL]AMINO] 4 OXOBUTANAMIDO]PENTYL] N4 [5 (N HYDROXYACETAMIDO)PENTYL]SUCCINAMIDE; N1 HYDROXY N1 [5 [4 [HYDROXY[5 [3 (6 HYDROXY 2,5,7,8 TETRA METHYLCHROMAN 2 YL)PROPANAMIDO]PENTYL]AMINO] 4 OXOBUTANAMIDO]PENTYL] N4 [5 (N HYDROXYACETAMIDO)PENTYL]SUCCINAMIDE; N1 HYDROXY N1 [5 [4 [HYDROXY[5 [3 (6 HYDROXY 2,5,7,8 TRIMETHYLCHROMAN 2 YL)PROPANAMIDO]PENTYL]AMINO] 4 OXOBUTANAMIDO]PENTYL] N4 [5 (N HYDROXYACETAMIDO)PENTYL]SUCCINAMIDE; N1 HYDROXY N1 [5 [4 [HYDROXY[5 [3 (6 HYDROXY 2,8 DIMETHYLCHROMAN 2 YL)PROPANAMIDO]PENTYL]AMINO] 4 OXOBUTANAMIDO]PENTYL] N4 [5 (N HYDROXYACETAMIDO)PENTYL]SUCCINAMIDE; N1 HYDROXY N1 [5 [4 [HYDROXY[5 [4 (3 METHYL 5 OXO 4,5 DIHYDRO 1H PYRAZOL 1 YL)BENZAMIDO]PENTYL]AMINO] 4 OXOBUTANAMIDO]PENTYL] N4 [5 (N HYDROXYACETAMIDO)PENTYL]SUCCINAMIDE; N1 [5 (3,5 DIMETHYLADAMANTANE 1 CARBOXAMIDO)PENTYL] N1 HYDROXY N4 [5 [N HYDROXY 4 [[5 (N HYDROXYACETAMIDO)PENTYL]AMINO] 4 OXOBUTANAMIDO]PENTYL]SUCCINAMIDE; NORPHENAZONE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 2,2'-AZINO-DI-(3-ETHYLBENZOTHIAZOLINE)-6-SULFONIC ACID; ANTIOXIDANT; ASCORBIC ACID; BENZOTHIAZOLE DERIVATIVE; DEFEROXAMINE; IRON; PLASMA PROTEIN; SULFONIC ACID DERIVATIVE;

ABTS RADICAL SCAVENGING ASSAY; ADULT; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; DRUG DESIGN; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; LIPOPHILICITY; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; METABOLISM; NERVE CELL; PATHOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; BENZOTHIAZOLES; BLOOD PROTEINS; DEFEROXAMINE; DISEASE MODELS, ANIMAL; IRON; IRON CHELATING AGENTS; MICE; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; SULFONIC ACIDS;

EID: 85023742552     PISSN: 17565901     EISSN: 1756591X     Source Type: Journal    
DOI: 10.1039/c7mt00039a     Document Type: Article

References (71)

1. L. Zecca M. B. Youdim P. Riederer J. R. Connor R. R. Crichton Iron, brain ageing and neurodegenerative disorders Nat. Rev. Neurosci. 2004 5 863 873
2. D. Athauda T. Foltynie The ongoing pursuit of neuroprotective therapies in Parkinson disease Nat. Rev. Neurol. 2015 11 25 40
3. E. J. Burton I. G. McKeith D. J. Burn E. D. Williams J. T. O'Brien Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls Brain 2004 127 791 800
4. H. Braak E. Ghebremedhin U. Rüb H. Bratzke K. Del Tredici Stages in the development of Parkinson's disease-related pathology Cell Tissue Res. 2004 318 121 134
5. D. Berg M. Gerlach M. B. Youdim K. L. Double L. Zecca P. Riederer G. Becker Brain iron pathways and their relevance to Parkinson's disease J. Neurochem. 2001 79 225 236
6. K. L. Double Neuronal vulnerability in Parkinson's disease Parkinsonism Relat. Disord. 2012 1851 S52 S54
7. D. B. Shachar N. Kahana V. Kampel A. Warshawsky M. B. Youdim Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats Neuropharmacology 2004 46 254 263
8. Y. Muñoz C. M. Carrasco J. D. Campos P. Aguirre T. Núñez Parkinson's disease: the mitochondria-iron link Parkinson's Dis. 2016 7049108
9. M. Ebadi S. K. Srinivasan M. D. Baxi Oxidative stress and antioxidant therapy in Parkinson's disease Prog. Neurobiol. 1996 48 1 19
10. J. Hagemeier J. J. G. Geurts R. Zivadinov Brain iron accumulation in aging and neurodegenerative disorders Expert Rev. Neurother. 2012 12 1467 1480
11. P. Lei S. Ayton D. I. Finkelstein L. Spoerri G. D. Ciccotosto D. K. Wright B. X. W. Wong P. A. Adlard R. A. Cherny L. Q. Lam B. R. Roberts I. Volitakis G. F. Egan C. A. McLean R. Cappai J. A. Duce A. I. Bush Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export Nat. Med. 2012 18 291 295
12. L. R. Perez K. J. Franz Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease Dalton Trans. 2010 39 2177 2187
13. A. P. Lan J. Chen Z. F. Chai Y. Hu The neurotoxicity of iron, copper and cobalt in Parkinson's disease through ROS-mediated mechanisms BioMetals 2016 29 665 678
14. H. Jiang J. Wang J. Rogers J. Xie Brain iron metabolism dysfunction in Parkinson's disease Mol. Neurobiol. 2017 54 3078 3101
15. A. M. Daugherty E. M. Haacke N. Raz Striatal iron content predicts its shrinkage and changes in verbal working memory after two years in healthy adults J. Neurosci. 2015 35 6731 6743
16. D. J. Hare P. Lei S. Ayton B. R. Roberts R. Grimm J. L. George D. P. Bishop A. D. Beavis S. J. Donovan G. McColl I. Volitakis C. L. Masters P. A. Adlard R. A. Cherny A. I. Bush D. I. Finkelstein P. A. Doble An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta Chem. Sci. 2014 5 2160 2169
17. S. Ayton P. Lei J. A. Duce B. X. W. Wong A. Sedjahtera P. A. Adlard A. I. Bush D. I. Finkelstein Ceruloplasmin dysfunction and therapeutic potential for Parkinson's disease Ann. Neurol. 2013 73 554 559
18. M. Smeyne Glutathione metabolism and Parkinson's disease Free Radical Biol. Med. 2013 62 13 25
19. A. Evers R. D. Hancock A. E. Martell R. J. Motekaitis Metal ion recognition in ligands with negatively charged oxygen donor groups. Complexation of Fe(iii), Ga(iii), In(iii), Al(iii), and other highly charged metal ions Inorg. Chem. 1989 28 2189 2195
20. S. S. Jamuar A. H. M. Lai Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia Ther. Adv. Hematol. 2012 3 299 307
21. II Eur. J. Inorg. Chem. 2004 4177 4192
22. N. F. Olivieri G. M. Brittenham Iron-chelating therapy and the treatment of Thalassemia Blood 1997 89 739 761
23. A. V. Hoffbrand How I treat transfusional iron overload Blood 2012 120 3657 3669
24. E. Gumienna-Kontecka V. M. Nurchi A. Szebesczyk P. Bilska K. Krzywoszynska H. Kozlowski Chelating agents as tools for the treatment of metal overload Z. Anorg. Allg. Chem. 2013 639 1321 1331
25. C. Rice-Evans E. Baysal S. Singh S. A. Jones J. G. Jones The interactions of desferrioxamine and hydroxypyridone compounds with haemoglobin and erythrocytes FEBS Lett. 1989 256 17 20
26. P. M. Ihnat J. L. Vennerstrom D. H. Robinson Synthesis and solution properties of deferoxamine amides J. Pharm. Sci. 2000 89 1525 1536
27. J. B. Lloyd H. Cable C. Rice-Evans Evidence that desferrioxamine cannot enter cells by passive diffusion Biochem. Pharmacol. 1991 41 1361 1363
28. D. Goswami M. T. Machini D. M. Silvestre C. S. Nomura B. P. Esposito Cell penetrating peptide (CPP)-conjugated desferrioxamine for enhanced neuroprotection: Synthesis and in vitro evaluation Bioconjugate Chem. 2014 25 2067 2080
29. J. Sripetchwandee S. Wongjaikan W. Krintratun N. Chattipakorn S. C. Chattipakorn A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload Neuroscience 2016 332 191 202
30. D. Stanic D. I. Finkelstein D. W. Bourke J. Drago M. K. Horne Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat Eur. J. Neurosci. 2003 18 1175 1188
31. K. E. Bowenkamp D. David P. L. Lapchak M. A. Henry A. C. Granholm B. J. Hoffer T. J. Mahalik 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor Exp. Brain Res. 1996 111 1 7
32. D. J. Hare P. A. Adlard P. A. Doble D. I. Finkelstein Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity Metallomics 2013 5 91 109
33. V. Jackson-Lewis S. Przedborski Protocol for the MPTP mouse model of Parkinson's disease Nat. Protoc. 2007 2 141 151
34. S. Roy J. E. Preston R. C. Hider Y. M. Ma Glucosylated deferiprone and its brain uptake: implications for developing glucosylated hydroxypyridinone analogues intended to cross the blood-brain barrier J. Med. Chem. 2010 53 5886 5889
35. R. J. Ward D. T. Dexter A. Florence F. Aouad R. C. Hider P. Jenner R. R. Crichton Brain iron content of the ferrocene-loaded rat: Its chelation and influence on dopamine metabolism Biochem. Pharmacol. 1995 49 1821 1826
36. D. Devos C. Moreau J. C. Devedijan J. Kluza M. Petrault C. Laloux A. Jonneaux G. Ryckewaert G. Garçon N. Rouaix A. Duhamel P. Jissendi K. Dujardin F. Auger L. Ravasi L. Hopes G. Grolez W. Firdaus B. Sablonnière I. Strubi-Vuillaume N. Zahr A. Destée J.-C. Corvol D. Pöltl M. Leist C. Rose L. Defebvre P. Marchetti Z. I. Cabantchik R. Bordet Targeting chelatable iron as a therapeutic modality in Parkinson's disease Antioxid. Redox Signaling 2014 21 195 210
37. J. Liu D. Obando L. G. Schipanski L. K. Groebler P. K. Witting D. S. Kalinowski D. R. Richardson R. Codd Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload J. Med. Chem. 2010 53 1370 1382
38. S. A. Hitchcock L. D. Pennington Structure-brain exposure relationships J. Med. Chem. 2006 49 7559 7583
39. J. R. Liddell D. Obando J. Liu G. Ganio I. Volitakis S. S. Mok P. J. Crouch A. R. White R. Codd Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease Free Radical Biol. Med. 2013 60 147 156
40. E. C. P. Alta D. Goswami M. T. Machini D. M. Silvestre C. S. Nomura B. P. Espósito Desferrioxamine-caffeine (DFCAF) as a cell permeant moderator of the oxidative stress caused by iron overload BioMetals 2014 27 1351 1360
41. G. R. Buettner In the absence of catalytic metals ascorbate does not autoxidize at pH 7: ascorbate as a test for catalytic metals J. Biochem. Biophys. Methods 1988 16 27 40
42. R. Re N. Pellegrini A. Proteggente A. Pannala M. Yang C. Rice-Evans Antioxidant activity applying an improved ABTS radical cation decolorization assay Free Radical Biol. Med. 1999 26 1231 1237
43. M. Etminan S. S. Gill A. Samii Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis Lancet Neurol. 2005 4 362 365
44. D. Q. Pham R. Plakogiannis Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2 Ann. Pharmacother. 2005 39 2065 2072
45. M. W. Fariss J.-G. Zhang Vitamin E therapy on Parkinson's disease Toxicology 2003 189 129 146
46. B. P. Esposito W. Breuer P. Sirankapracha P. Pootrakul C. Hershko I. Cabantchik Labile plasma iron in iron overload: Redox activity and susceptibility of chelation Blood 2003 102 2670 2677
47. C. Vitali C. L. Wellington L. Calabresi HDL and cholesterol handling in the brain Cardiovasc. Res. 2014 103 405 413
48. D. Goti A. Hrzenjak S. Levak-Frank S. Frank D. R. van der Westhuyzen E. Malle W. Sattler Scavenger receptor class B, type I is expressed in porcine brain capillary endothelial cells and contributes to selective uptake of HDL-associated vitamin E J. Neurochem. 2001 76 498 508
49. U. Panzenboeck Z. Balazs A. Sovic A. Hrzenjak S. Levak-Frank A. Wintersperger E. Malle W. Sattler ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells J. Biol. Chem. 2002 277 42781 42789
50. J. M. Zingg P. Kempna M. Paris E. Reiter L. Villacorta R. Cipollone A. Munteanu C. De Pascale S. Menini A. Cueff M. Arock A. Azzi R. Ricciarelli Characterization of three human sec14p-like proteins: α-Tocopherol transport activity and expression pattern in tissues Biochimie 2008 90 1703 1715
51. I. Kratzer E. Bernhart A. Wintersperger A. Hammer S. Waltl E. Malle G. Sperk G. Wietzorrek H. Dieplinger W. Sattler Afamin is synthesized by cerebrovascular endothelial cells and mediates α-tocopherol transport across an in vitro model of the blood-brain barrier J. Neurochem. 2009 108 707 718
52. C. Desrumaux P. Y. Risold H. Schroeder V. Deckert D. Masson A. Athias H. Laplanche N. Le Guern D. Blache X. C. Jiang A. R. Tall D. Desor L. Lagrost Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice FASEB J. 2005 19 296 297
53. S.-S. Jiao X.-Q. Yao Y.-H. Liu Q.-H. Wang F. Zeng J.-J. Lu J. Liu C. Zhu L.-L. Shen C.-H. Liu Y.-R. Wang G.-H. Zeng A. Parikh J. Chen C.-R. Liang Y. Xiang X.-L. Bu J. Deng J. Li J. Xu Y.-Q. Zeng X. Xu H. W. Xu J.-H. Zhong H.-D. Zhou X.-F. Zhou Y.-J. Wang Edaravone alleviates Alzheimer's disease-type pathologies and cognitive defects Proc. Natl. Acad. Sci. U. S. A. 2015 112 5225 5230
54. G. L. Zhang W. G. Zhang Y. Du L. Yao H. Sun R. Zhang E. Liu N. Bu H. Q. Wu L. Zhang T. T. Li Y. Y. Gio Edaravone ameliorates oxidative damage associated with Aβ25-35 treatment in PC12 cells J. Mol. Neurosci. 2013 50 494 503
55. J. Liu D. Obando V. Liao T. Lifa R. Codd The many faces of the adamantyl group in drug design Eur. J. Med. Chem. 2011 46 1949 1963
56. N. J. Waters R. Jones G. Williams B. Sohal Validation of a rapid equilibrium dialysis approach for the measurment of plasma protein binding J. Pharm. Sci. 2008 97 4586 4595
57. D. S. Wishart C. Knox A. C. Guo S. Shrivastava M. Hassanali P. Stothard Z. Chang J. Woolsey DrugBank: a comprehensive resource for in silico drug discovery and exploration Nucleic Acids Res. 2006 34 D668 D672
58. B. Halliwell Role of free radicals in the neurodegenerative diseases Drugs Aging 2001 18 685 716
59. G. R. Buettner Ascorbate autoxidation in the presence of iron and copper chelates Free Radical Res. Commun. 1986 1 349 353
60. R. F. Jameson W. Linert Complex formation followed by internal electron transfer: The reaction between cysteine and iron(iii) Monatsh. Chem. 1991 122 887 906
61. R. Panossian G. Terzian M. Guiliano Coordination iron-cysteine and methylcysteine complexes Spectrosc. Lett. 1979 12 715 723
62. T. J. Telfer J. R. Liddell C. Duncan A. R. White R. Codd Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinson's disease Bioorg. Med. Chem. Lett. 2017 27 1698 1704
63. V. Jackson-Lewis M. Jakowec R. E. Burke S. Przedborski Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurodegeneration 1995 4 257 269
64. G. Park Y.-J. Park H. O. TYang M. S. Oh Ropinirole protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism Pharmacol., Biochem. Behav. 2013 104 163 168
65. U. Kotowska K. Garbowska V. A. Isidorov Distribution coefficients of phthalates between absorption fiber and water and its use in quantitative analysis Anal. Chim. Acta 2006 560 110 117
66. Y. Zhao J. Jona D. T. Chow H. Rong D. Semin X. Xia R. Zanon C. Spancake E. Maliski High-throughput logP measurement using parallel liquid chromatography/ultraviolet/mass spectrometry and sample-pooling Rapid Commun. Mass Spectrom. 2002 16 1548 1555
67. A. Leo C. Hansch D. Elkins Partition coefficients and their uses Chem. Rev. 1971 71 525 616
68. C. Yamagami K. Araki K. Ohnishi K. Hanasato H. Inaba M. Aono A. Ohta Measurement and prediction of hydrophobicity parameters for highly lipophilic compounds: Application of the HPLC column-switching technique to measurement of log P of diarylpyrazines J. Pharm. Sci. 1999 88 1299 1304
69. M. A. Santos S. Gama M. Gil L. Gano A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones Hemoglobin 2008 32 147 156
70. R. A. Yokel A. K. Datta E. G. Jackson Evaluation of potential aluminum chelators in vitro by aluminum solubilization ability, aluminum mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminum J. Pharmacol. Exp. Ther. 1991 257 100 106
71. A. Berthod S. Carda-Broch A new class of solvents forCCC: The room temperature ionic liquids J. Liq. Chromatogr. Relat. Technol. 2003 26 1493 1508